Tokio Marine Asset Management Co. Ltd. Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Tokio Marine Asset Management Co. Ltd. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,811 shares of the biopharmaceutical company’s stock after buying an additional 1,664 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $2,577,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. Clearbridge Investments LLC lifted its holdings in Gilead Sciences by 179.0% in the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after buying an additional 2,915,141 shares during the period. abrdn plc boosted its position in shares of Gilead Sciences by 89.0% in the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after purchasing an additional 1,772,887 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $133,584,000. AEGON ASSET MANAGEMENT UK Plc bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $63,971,000. Finally, Bailard Inc. boosted its position in shares of Gilead Sciences by 9,100.7% in the 3rd quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock worth $54,133,000 after purchasing an additional 714,494 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GILD shares. Royal Bank of Canada dropped their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. Barclays decreased their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Cantor Fitzgerald decreased their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. Wells Fargo & Company decreased their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Finally, Oppenheimer restated an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a report on Friday, April 19th. Ten equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and an average target price of $84.57.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $1.78 during mid-day trading on Thursday, hitting $65.30. 6,080,275 shares of the company’s stock traded hands, compared to its average volume of 7,293,857. The company’s 50-day moving average is $71.56 and its two-hundred day moving average is $76.39. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The company has a market capitalization of $81.30 billion, a P/E ratio of 14.98, a PEG ratio of 0.96 and a beta of 0.19. Gilead Sciences, Inc. has a 1 year low of $65.26 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. During the same period last year, the company earned $1.67 earnings per share. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 5.24 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.72%. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.